Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease
Aim. Comparative assessment of the economic results of rivaroxaban/acetylsalicylic acid (ASA) combination and ASA monotherapy use in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD). Material and methods. Based on the results of a large international multicenter, pl...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2019-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3584 |
| _version_ | 1826561160986492928 |
|---|---|
| author | N. V. Pogosova A. V. Panov A. Yu. Kulikov V. G. Serpik V. A. Kulikov |
| author_facet | N. V. Pogosova A. V. Panov A. Yu. Kulikov V. G. Serpik V. A. Kulikov |
| author_sort | N. V. Pogosova |
| collection | DOAJ |
| description | Aim. Comparative assessment of the economic results of rivaroxaban/acetylsalicylic acid (ASA) combination and ASA monotherapy use in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD). Material and methods. Based on the results of a large international multicenter, placebo-controlled, randomized clinical trial COMPASS, a model that evaluated the clinical outcomes of rivaroxaban/ASA combination and ASA monotherapy was formed. The economic results using cost and cost-effectiveness analyses, and budget impact analysis for two years were also calculated. The analysis took into account both direct medical costs (expenses for treatment, hospitalization due to complications, rehabilitation) financed under the compulsory health insurance, as well as indirect costs (loss of GDP due to disability or death). The calculation was made by accounting 100,000 patients with CAD and/or PAD.Results. Modeling of clinical outcomes per 100,000 patients based on COMPASS results showed a decrease of stroke prevalence by 649 cases, myocardial infarction — 301 cases, amputations — 478 cases, cardiovascular mortality — 476 cases when using rivaroxaban/ASA combination compared with ASA monotherapy. The cost-effectiveness analysis showed that rivaroxaban/ASA combination has greater clinical efficacy and lower costs in comparison with ASA monotherapy. Budget impact analysis showed that the switching of 100,000 patients with CAD and/or PAD from ASA monotherapy to rivaroxaban/ASA combination leads to budget savings of 1,026 million rubles in two years. This is due to a decrease in the incidence of cardiovascular events.Conclusion. It was found that the use of a rivaroxaban/ASA combination in comparison with ASA monotherapy in patients with CAD and/or PAD can both decrease a number of complications and lead to cost savings, despite the initially higher cost pharmacotherapy. |
| first_indexed | 2024-04-09T20:45:23Z |
| format | Article |
| id | doaj.art-28ac9d611dc84e1b927d5a026b5b6f97 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2025-03-14T09:27:46Z |
| publishDate | 2019-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-28ac9d611dc84e1b927d5a026b5b6f972025-03-02T11:42:49Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202019-12-01012768610.15829/1560-4071-2019-12-76-862790Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery diseaseN. V. Pogosova0A. V. Panov1A. Yu. Kulikov2V. G. Serpik3V. A. Kulikov4National Medical Research Center of CardiologyAlmazov National Medical Research CenterI. M. Sechenov First Moscow State Medical UniversityI. M. Sechenov First Moscow State Medical UniversityI. M. Sechenov First Moscow State Medical UniversityAim. Comparative assessment of the economic results of rivaroxaban/acetylsalicylic acid (ASA) combination and ASA monotherapy use in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD). Material and methods. Based on the results of a large international multicenter, placebo-controlled, randomized clinical trial COMPASS, a model that evaluated the clinical outcomes of rivaroxaban/ASA combination and ASA monotherapy was formed. The economic results using cost and cost-effectiveness analyses, and budget impact analysis for two years were also calculated. The analysis took into account both direct medical costs (expenses for treatment, hospitalization due to complications, rehabilitation) financed under the compulsory health insurance, as well as indirect costs (loss of GDP due to disability or death). The calculation was made by accounting 100,000 patients with CAD and/or PAD.Results. Modeling of clinical outcomes per 100,000 patients based on COMPASS results showed a decrease of stroke prevalence by 649 cases, myocardial infarction — 301 cases, amputations — 478 cases, cardiovascular mortality — 476 cases when using rivaroxaban/ASA combination compared with ASA monotherapy. The cost-effectiveness analysis showed that rivaroxaban/ASA combination has greater clinical efficacy and lower costs in comparison with ASA monotherapy. Budget impact analysis showed that the switching of 100,000 patients with CAD and/or PAD from ASA monotherapy to rivaroxaban/ASA combination leads to budget savings of 1,026 million rubles in two years. This is due to a decrease in the incidence of cardiovascular events.Conclusion. It was found that the use of a rivaroxaban/ASA combination in comparison with ASA monotherapy in patients with CAD and/or PAD can both decrease a number of complications and lead to cost savings, despite the initially higher cost pharmacotherapy.https://russjcardiol.elpub.ru/jour/article/view/3584coronary artery diseaseperipheral arterial diseaserivaroxabanacetylsalicylic acidcost-effectiveness analysisbudget impact analysis |
| spellingShingle | N. V. Pogosova A. V. Panov A. Yu. Kulikov V. G. Serpik V. A. Kulikov Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease Российский кардиологический журнал coronary artery disease peripheral arterial disease rivaroxaban acetylsalicylic acid cost-effectiveness analysis budget impact analysis |
| title | Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease |
| title_full | Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease |
| title_fullStr | Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease |
| title_full_unstemmed | Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease |
| title_short | Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease |
| title_sort | pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and or peripheral artery disease |
| topic | coronary artery disease peripheral arterial disease rivaroxaban acetylsalicylic acid cost-effectiveness analysis budget impact analysis |
| url | https://russjcardiol.elpub.ru/jour/article/view/3584 |
| work_keys_str_mv | AT nvpogosova pharmacoeconomicstudyofrivaroxabanandacetylsalicylicacidcombinationuseinpatientswithcoronaryarterydiseaseandorperipheralarterydisease AT avpanov pharmacoeconomicstudyofrivaroxabanandacetylsalicylicacidcombinationuseinpatientswithcoronaryarterydiseaseandorperipheralarterydisease AT ayukulikov pharmacoeconomicstudyofrivaroxabanandacetylsalicylicacidcombinationuseinpatientswithcoronaryarterydiseaseandorperipheralarterydisease AT vgserpik pharmacoeconomicstudyofrivaroxabanandacetylsalicylicacidcombinationuseinpatientswithcoronaryarterydiseaseandorperipheralarterydisease AT vakulikov pharmacoeconomicstudyofrivaroxabanandacetylsalicylicacidcombinationuseinpatientswithcoronaryarterydiseaseandorperipheralarterydisease |